文献速递肝病

丙型肝炎直接抗病毒治疗期间及治疗后的患者报告症状:PROP UP研究

Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
PubMed 文献 · J Hepatol · 2019-05-13

PROP UP是一项美国多中心观察性研究,纳入2016-2017年接受直接抗病毒药物治疗的1601例丙型肝炎患者,评估治疗期间及治疗后患者报告结局变化。总体队列治疗期间症状均值轻度改善但未达5%最小重要变化阈值,获得持续病毒学应答者停药后疲劳、睡眠障碍和功能健康状态改善达到阈值。

要点

  • 治疗期间总体症状均值轻度改善但未达5%最小重要变化变化阈值,21-53%患者改善>5%,23-36%症状加重>5%。
  • 1410例可评估持续病毒学应答患者中95%获得持续病毒学应答,获得应答者疲劳、睡眠障碍和功能健康状态改善达到5%阈值。
  • 年龄35-55岁、基线心理健康问题及合并症较多是患者报告结局改善的预测因素。

核心结论

  • 在真实世界临床实践中,直接抗病毒治疗期间及治疗后患者体验存在异质性,症状改善在年轻、基线有心理健康问题及多种合并症的患者中更为明显。

研究设计与样本

  • PROP UP为美国多中心观察性研究,纳入2016-2017年接受直接抗病毒药物治疗的1601例丙型肝炎患者,患者报告结局数据在基线、治疗早期、治疗后期及治疗后3个月收集。

主要发现

  • 1564例患者中55%为男性,39%为非白人,47%有肝硬化;索磷布韦/来迪派韦用于63%,索磷布韦/维帕他韦用于21%,格拉瑞韦/艾尔巴韦用于11%,帕利瑞韦/奥比他韦/利托那韦+达塞布韦用于5%。
  • 直接抗病毒治疗期间总体队列患者报告结局均值轻度改善但未达5%最小重要变化阈值,21-53%患者报告结局改善>5%,23-36%症状加重>5%。
  • 1410例可评估持续病毒学应答患者中95%获得持续病毒学应答;获得持续病毒学应答者所有患者报告结局均值改善,疲劳、睡眠障碍和功能健康状态达到5%最小重要变化阈值。
  • 回归分析确定年龄35-55岁、基线心理健康问题及较高合并症数量为患者报告结局改善的预测因素。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: A comprehensive analysis of changes in symptoms and functioning during and after direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection has not been conducted for patients treated in real-world clinical settings. Therefore, we evaluated patient-reported outcomes (PROs) in a diverse cohort of patients with HCV treated with commonly prescribed DAAs. METHODS: PROP UP is a US multicenter observational study of 1,601 patients with HCV treated with DAAs in 2016-2017. PRO data were collected at baseline (T1), early on-treatment (T2), late on-treatment (T3) and 3-months post-treatment (T4). PRO mean change scores were calculated from baseline and a minimally important change (MIC) threshold was set at 5%. Regression analyses investigated patient and treatment characteristics independently associated with PRO changes on-treatment and post-treatment. RESULTS: Of 1,564 patients, 55% were male, 39% non-white, 47% had cirrhosis. Sofosbuvir/ledipasvir was prescribed to 63%, sofosbuvir/velpatasvir to 21%, grazoprevir/elbasvir to 11%, and paritaprevir/ombitasvir/ritonavir + dasabuvir to 5%. During DAA therapy, mean PRO scores improved slightly in the overall cohort, but did not reach the 5% MIC threshold. Between 21-53% of patients experienced >5% improved PROs while 23-36% experienced >5% worse symptoms. Of 1,410 patients with evaluable sustained virologic response (SVR) data, 95% achieved SVR. Among those with SVR, all mean PRO scores improved, with the 5% MIC threshold met for fatigue, sleep disturbance, and functioning well-being. Regression analyses identified subgroups, defined by age 35-55, baseline mental health issues and a higher number of health comorbidities as predictors of PRO improvements. CONCLUSIONS: In real-world clinical practices, we observed heterogeneous patient experiences during and after DAA treatment. Symptom improvements were more pronounced in younger patients, those with baseline mental health issues and multiple comorbidities. LAY SUMMARY: Patients who received direct-acting antiviral medications for hepatitis C at several liver centers in the US did not generally experience significant changes in baseline symptoms during treatment. We observed a full range of patient experiences with some patients experiencing substantial symptom improvements, yet others experiencing less improvements and some even experiencing a worsening of symptoms. The 1,346 patients who were cured of hepatitis C experienced improvements in fatigue, sleep disturbance, and functional well-being, and trends for improved pain and depression; whereas the 64 who were not cured experienced minimal improvements. Clinicaltrial.gov: NCT02601820.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Evon DM, Sarkar S, Amador J, et al. Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. J Hepatol. 2019. PMID: 31096006. doi:10.1016/j.jhep.2019.04.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。